← Back to Search

Exercise Timing for Type 2 Diabetes

N/A
Recruiting
Led By Steven K Malin, PhD
Research Sponsored by Rutgers, The State University of New Jersey
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Subjects currently taking medications that affect heart rate and rhythm (i.e. Ca++ channel blockers, nitrates, alpha- or beta-blockers)
Male or female >30 and <70 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up over the course of 2 weeks.
Awards & highlights

Study Summary

This trial will test whether Noom, a weight-loss app, helps people with type 2 diabetes better stick to their exercise and diet plan, leading to more weight loss and better health.

Who is the study for?
Adults aged 30-70 with type 2 diabetes, a BMI between 28 and 45, not currently on weight loss meds or insulin therapy. Mustn't have significant heart, liver, kidney diseases or cancer. Non-smokers only (or those who quit over a year ago), not pregnant/nursing, and haven't been exercising regularly.Check my eligibility
What is being tested?
The trial is testing the effectiveness of Noom for improving diet adherence during exercise in the morning vs. afternoon for better weight loss and heart health in type 2 diabetics. It's checking if this leads to better blood sugar control and blood pressure.See study design
What are the potential side effects?
Since this study involves lifestyle changes rather than medication, side effects may include typical exercise-related issues such as muscle soreness or fatigue but are generally minimal compared to drug interventions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am currently on medication that affects my heart rate or rhythm.
Select...
I am between 30 and 70 years old.
Select...
I have been diagnosed with type 2 diabetes.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~over the course of 2 weeks.
This trial's timeline: 3 weeks for screening, Varies for treatment, and over the course of 2 weeks. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Body Weight
Secondary outcome measures
Flow-mediated dilation
Glucose Tolerance

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Exercise MorningExperimental Treatment2 Interventions
If subjects are randomly assigned to this group, they will participate in exercise training in the morning at a moderate to hard intensity. Subjects will be asked to regularly engage in morning exercise while supervised for about 2 weeks.
Group II: Exercise AfternoonActive Control1 Intervention
If subjects are assigned to this group, they will participate in the same exercise program but after in the afternoon.

Find a Location

Who is running the clinical trial?

Rutgers, The State University of New JerseyLead Sponsor
426 Previous Clinical Trials
64,082 Total Patients Enrolled
2 Trials studying Metabolic Syndrome
160 Patients Enrolled for Metabolic Syndrome
Noom Inc.Industry Sponsor
15 Previous Clinical Trials
2,398 Total Patients Enrolled
Steven K Malin, PhDPrincipal InvestigatorRutgers University - New Brunswick
3 Previous Clinical Trials
200 Total Patients Enrolled
2 Trials studying Metabolic Syndrome
160 Patients Enrolled for Metabolic Syndrome

Media Library

Exercise Afternoon Clinical Trial Eligibility Overview. Trial Name: NCT05108987 — N/A
Metabolic Syndrome Research Study Groups: Exercise Afternoon, Exercise Morning
Metabolic Syndrome Clinical Trial 2023: Exercise Afternoon Highlights & Side Effects. Trial Name: NCT05108987 — N/A
Exercise Afternoon 2023 Treatment Timeline for Medical Study. Trial Name: NCT05108987 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

For whom is eligibility criteria established to join this medical trial?

"This clinical study seeks 63 individuals, aged 30 to 70 years old with metabolic syndrome. To be eligible for the trial, patients must have a BMI between 28 and 45 kg/m2, not be taking any cardiovascular medications (i.e. calcium channel blockers, nitrates or alpha- or beta-blockers) and are of either gender."

Answered by AI

Does the research protocol allow for individuals over 35 years to be part of this investigation?

"This medical trial is open to participants aged between 30 and 70."

Answered by AI

Are there any opportunities for participants to join this clinical trial?

"The information on clinicaltrials.gov indicates that this trial has been ongoing since September 25th 2021, and was last updated on January 12th 2022, meaning it is still actively recruiting participants."

Answered by AI

What is the current participant count for this investigation?

"Affirmative. According to the information present on clinicaltrials.gov, this medical experiment has recently opened for enrollment and is actively recruiting patients who fit its criteria. Initially posted in September of 2021 and most recently updated in January 2022, 63 individuals from 3 different locations are desired participants."

Answered by AI

Who else is applying?

What state do they live in?
New York
What portion of applicants met pre-screening criteria?
Met criteria
~9 spots leftby Sep 2024